The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform

Drew M. Pardoll - One of the best experts on this subject based on the ideXlab platform.

  • cancer immunotherapy breaking the barriers to harvest the crop
    Nature Medicine, 2004
    Co-Authors: Drew M. Pardoll, James P Allison
    Abstract:

    Successful translation of modern Molecular Immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

  • spinning Molecular Immunology into successful immunotherapy
    Nature Reviews Immunology, 2002
    Co-Authors: Drew M. Pardoll
    Abstract:

    Until recently, immunotherapies have been of limited success, particularly against cancer. However, recent insights into the cells, molecules and signalling pathways that regulate immune responsiveness are providing new approaches for immunotherapy. In this article, I review some of the most promising Molecular and cellular targets for immunotherapy and discuss approaches that use these targets to amplify immune responses and potentially break antigen-specific tolerance. These strategies provide a blueprint for the development of successful immunotherapy over the next decade.

  • Spinning Molecular Immunology into successful immunotherapy
    Nature Reviews Immunology, 2002
    Co-Authors: Drew M. Pardoll
    Abstract:

    DC derived-exosomes are nanomeric vesicles harboring functional MHC/peptide complexes capable of promoting T cell immune responses and tumor rejection. Here we report the feasability and safety of the first Phase I clinical trial using autologous exosomes pulsed with MAGE 3 peptides for the immunization of stage III/IV melanoma patients. Secondary endpoints were the monitoring of T cell responses and the clinical outcome. Exosomes were purified from day 7 autologous monocyte derived-DC cultures. Fifteen patients fullfilling the inclusion criteria (stage IIIB and IV, HLA-A1+, or -B35+ and HLA-DPO4+ leukocyte phenotype, tumor expressing MAGE3 antigen) were enrolled from 2000 to 2002 and received four exosome vaccinations. Two dose levels of either MHC class II molecules (0.13 versus 0.40 × 1014 molecules) or peptides (10 versus 100 μg/ml) were tested. Evaluations were performed before and 2 weeks after immunization. A continuation treatment was performed in 4 cases of non progression. The GMP process allowed to harvest about 5 × 1014 exosomal MHC class II molecules allowing inclusion of all 15 patients. There was no grade II toxicity and the maximal tolerated dose was not achieved. One patient exhibited a partial response according to the RECIST criteria. This HLA-B35+/A2+ patient vaccinated with A1/B35 defined CTL epitopes developed halo of depigmentation around naevi, a MART1-specific HLA-A2 restricted T cell response in the tumor bed associated with progressive loss of HLA-A2 and HLA-BC molecules on tumor cells during therapy with exosomes. In addition, one minor, two stable and one mixed responses were observed in skin and lymph node sites. MAGE3 specific CD4+ and CD8+ T cell responses could not be detected in peripheral blood. The first exosome Phase I trial highlighted the feasibility of large scale exosome production and the safety of exosome administration.

Shiv Pillai - One of the best experts on this subject based on the ideXlab platform.

Abul K Abbas - One of the best experts on this subject based on the ideXlab platform.

Andrew H Lichtman - One of the best experts on this subject based on the ideXlab platform.

Devendra K Agrawal - One of the best experts on this subject based on the ideXlab platform.

  • cellular and Molecular Immunology of lung cancer therapeutic implications
    Expert Review of Clinical Immunology, 2014
    Co-Authors: Austin Huy Nguyen, Ilya Berim, Devendra K Agrawal
    Abstract:

    Although the incidence of lung cancer is declining, the prognosis remains poor. This is likely due to lack of early detection and only recent developments in selective cancer therapies. Key immune cells involved in the pathogenesis of lung cancer include CD4+ T lymphocytes, macrophages, dendritic cells and NK cells. The growing understanding of these cells indicates a highly complex and intertwined network of their involvement in each stage of lung cancer. Immune cell types and numbers affect prognosis and could offer an opportunity for clinical therapeutic applications. However, an incomplete understanding of immune cell involvement and the underlying processes in lung cancer still remain. Deeper investigation focusing on the role of the immune cells will further the understanding of lung carcinogenesis and develop novel therapeutic approaches for the treatment and management of patients with more specialized and selective lung cancer.